# A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

> **NCT06057038** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 42 (estimated)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **BIOLOGICAL:** GEN1042
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT06057038
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-24
- **Primary completion:** 2026-11-28
- **Final completion:** 2026-11-28
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057038, "A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06057038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*